This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Women's Excellence in Bladder Control
Medications that treat overactive bladder (OAB) have notorious side effects such as dry mouth, constipation, and urinary retention. Women’s Excellence in Bladder Control is now trialing and sampling a brand new medication that treats OAB differently.
Shelby Township, Michigan (PRWEB) February 20, 2013
Medications that treat overactive bladder (OAB) fall under a class of drugs called “anticholinergics”. Anticholinergic drugs are antispasmodic agents that inhibit the action of acetylcholine thereby stopping the transmission of parasympathetic nerve impulses and lessening the spasms of smooth muscle in the gastrointestinal tract and in the bladder. They are routinely used to treat spasms or conditions related to the bladder or gastrointestinal motility. Although these agents have been helpful in treating OAB symptoms over many years, some patients find the side effects of these medications intolerable.
Anticholinergic medications used to treat OAB can cause a variety of unpleasant side effects. In most patients, these side effects are mild and tolerable, but in some patients may be severe and intolerable. Common side effects caused by anticholinergic medications include: dizziness, constipation, urinary retention, and dry mouth. These side effects can be severe enough to cause a patient to quit the medication leaving them with no other oral medication option – till now.
Astellas pharmaceuticals has recently put on the market a new medication to treat OAB, it’s called Myrbetriq (mirabegron). The agent is as unique as its name and might just become a go to medication for those patients who fail traditional anticholinergic OAB therapy. Myrbetriq is not an anticholinergic drug. It is a beta-3 adrenergic agonist but relaxes the bladder smooth muscle just as anticholinergics do. Myrbetriq can help with symptoms of urge incontinence, urgency, and frequency. It also helps to increase the bladder’s capacity to hold a greater amount of urine. Women’s Excellence in Bladder Control is pleased to now offer this option to patients who cannot tolerate the side effects of traditional anticholinergics.
The most common side effects of Myrbetriq were increased blood pressure, common cold symptoms (nasopharyngitis), urinary tract infection, and headache. According to Debbie Henry, MSN, NP-C, nurse practitioner at Women’s Excellence in Bladder Control, “There are always going to be side effects with any medication. The question is ‘Are the side effects tolerable?'. We always start patients on a 2 week sample trial and have them return to the office for a follow up on the sample drug's effectiveness and tolerability; We take both into account. A drug can certainly be effective but if it is not tolerable, it is probably not the best option for the patient. This gives us an opportunity to try something else and find the best fit. The early feedback on Myrbetriq has been promising. It is definitely an option for patients who have normal blood pressure and OAB symptoms”.
Founded by Dr. Jonathan Zaidan, Women’s Excellence is the most comprehensive obstetric and gynecologic office in Michigan specializing in minimally invasive surgical procedures, treatment of female urinary incontinence and other female urological conditions, as well as minimally invasive vaginal and pelvic organ prolapse (POP) conditions. The knowledgeable, well trained, compassionate physicians and healthcare providers of Women’s Excellence in Bladder Control are now accepting new patients. Call for an appointment today or visit http://www.centerofbladdercontrol.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/2/prweb10446133.htm